New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback